Do analysts prefer BCTX or CODX?

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 7,037.57%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer BCTX or CODX?

In the previous week, Co-Diagnostics had 4 more articles in the media than Briacell Therap. MarketBeat recorded 7 mentions for Co-Diagnostics and 3 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.21 beat Co-Diagnostics' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CODX or RADX?

Radiopharm Theranostics has higher revenue and earnings than Co-Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Co-Diagnostics $620K 10.65 -$46.90M -$10.32 N/A Radiopharm Theranostics $1.88M 13.45 -$37.43M N/A N/A

Does the media favor CODX or RADX?

In the previous week, Co-Diagnostics had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 7 mentions for Co-Diagnostics and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.11 beat Co-Diagnostics' score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NXTC or CODX more profitable?

NextCure has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. NextCure's return on equity of -154.62% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% Co-Diagnostics -6,531.77% -210.99% -174.97%

Co-Diagnostics (CODX) Competitors

$0.95 +0.01 (+0.57%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.99 +0.05 (+5.11%)

As of 09/18/2026 07:59 PM Eastern

Compare

CODX vs. BCTX, SGMO, RADX, NXTC, and BRNS

Should you buy Co-Diagnostics stock or one of its competitors? Co-Diagnostics's main competitors and comparable companies include Briacell Therap (BCTX), Sangamo Therapeutics (SGMO), Radiopharm Theranostics (RADX), NextCure (NXTC), and Barinthus Biotherapeutics (BRNS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Co-Diagnostics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Briacell Therap has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market.

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 7,037.57%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Co-Diagnostics had 4 more articles in the media than Briacell Therap. MarketBeat recorded 7 mentions for Co-Diagnostics and 3 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.21 beat Co-Diagnostics' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Briacell Therap has higher earnings, but lower revenue than Co-Diagnostics. Briacell Therap is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Co-Diagnostics	$620K	10.65	-$46.90M	-$10.32	N/A

Briacell Therap has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Briacell Therap's return on equity of -153.53% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Summary

Co-Diagnostics beats Briacell Therap on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to Sangamo Therapeutics?

Co-Diagnostics (NASDAQ:CODX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Co-Diagnostics has higher earnings, but lower revenue than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	10.65	-$46.90M	-$10.32	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Co-Diagnostics has a beta of 2.85, suggesting that its share price is 185% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

In the previous week, Co-Diagnostics had 7 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 7 mentions for Co-Diagnostics and 0 mentions for Sangamo Therapeutics. Co-Diagnostics' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Co-Diagnostics	Neutral
Sangamo Therapeutics	Neutral

Sangamo Therapeutics has a net margin of -310.81% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 7,037.57%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Co-Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Co-Diagnostics beats Sangamo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Radiopharm Theranostics?

Co-Diagnostics (NASDAQ:CODX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

15.0% of Co-Diagnostics shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Co-Diagnostics currently has a consensus price target of $67.50, indicating a potential upside of 7,037.57%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 528.93%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Co-Diagnostics had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 7 mentions for Co-Diagnostics and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.11 beat Co-Diagnostics' score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Co-Diagnostics has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Radiopharm Theranostics has higher revenue and earnings than Co-Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	10.65	-$46.90M	-$10.32	N/A
Radiopharm Theranostics	$1.88M	13.45	-$37.43M	N/A	N/A

Radiopharm Theranostics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Radiopharm Theranostics' return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Radiopharm Theranostics beats Co-Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to NextCure?

NextCure (NASDAQ:NXTC) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

NextCure has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. NextCure's return on equity of -154.62% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market.

42.7% of NextCure shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Co-Diagnostics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Co-Diagnostics	$620K	10.65	-$46.90M	-$10.32	N/A

In the previous week, Co-Diagnostics had 7 more articles in the media than NextCure. MarketBeat recorded 7 mentions for Co-Diagnostics and 0 mentions for NextCure. NextCure's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Overall Sentiment
NextCure	Neutral
Co-Diagnostics	Neutral

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 210.46%. Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 7,037.57%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Co-Diagnostics beats NextCure on 8 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Co-Diagnostics had 7 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 7 mentions for Co-Diagnostics and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Co-Diagnostics	Neutral

Barinthus Biotherapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Barinthus Biotherapeutics' return on equity of -59.15% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Barinthus Biotherapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 440.54%. Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 7,037.57%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Barinthus Biotherapeutics has a beta of -0.37, indicating that its stock price is 137% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market.

Co-Diagnostics has higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
Co-Diagnostics	$620K	10.65	-$46.90M	-$10.32	N/A

Summary

Co-Diagnostics beats Barinthus Biotherapeutics on 8 of the 14 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.56M	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-0.09	14.30	275.79	25.40
Price / Sales	10.65	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	0.10	15.45	10.46	6.33
Net Income	-$46.90M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-15.56%	-1.21%	0.59%	1.12%
1 Month Performance	-14.03%	-4.42%	-2.01%	-2.67%
1 Year Performance	-92.80%	37.81%	18.09%	6.01%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	2.4225 of 5 stars	$0.95 +0.6%	$67.50 +7,037.6%	-92.7%	$6.56M	$620K	N/A	115	News Coverage Short Interest Decrease
BCTX Briacell Therap	0.3568 of 5 stars	$3.58 +0.3%	N/A	-53.6%	$31.15M	N/A	N/A	8	News Coverage Short Interest Increase
SGMO Sangamo Therapeutics	1.0111 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480	News Coverage
RADX Radiopharm Theranostics	2.8092 of 5 stars	$2.12 +1.9%	$11.00 +418.9%	-74.2%	$30.66M	$1.88M	N/A	N/A
NXTC NextCure	3.5234 of 5 stars	$8.42 +7.7%	$19.00 +125.7%	+9.7%	$30.40M	N/A	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. BCTX, SGMO, RADX, NXTC, and BRNS

How does Co-Diagnostics compare to Briacell Therap?

Summary

How does Co-Diagnostics compare to Sangamo Therapeutics?

Summary

How does Co-Diagnostics compare to Radiopharm Theranostics?

Summary

How does Co-Diagnostics compare to NextCure?

Summary

How does Co-Diagnostics compare to Barinthus Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. BCTX, SGMO, RADX, NXTC, and BRNS

How does Co-Diagnostics compare to Briacell Therap?

Do insiders and institutionals have more ownership in BCTX or CODX?

Which has more volatility & risk, BCTX or CODX?

Do analysts prefer BCTX or CODX?

Does the media prefer BCTX or CODX?

Which has stronger valuation & earnings, BCTX or CODX?

Is BCTX or CODX more profitable?

Summary

How does Co-Diagnostics compare to Sangamo Therapeutics?

Which has stronger earnings & valuation, CODX or SGMO?

Do institutionals and insiders believe in CODX or SGMO?

Which has more volatility & risk, CODX or SGMO?

Does the media prefer CODX or SGMO?

Is CODX or SGMO more profitable?

Do analysts prefer CODX or SGMO?

Summary

How does Co-Diagnostics compare to Radiopharm Theranostics?

Do insiders and institutionals have more ownership in CODX or RADX?

Do analysts recommend CODX or RADX?

Does the media favor CODX or RADX?

Which has more risk & volatility, CODX or RADX?

Which has preferable earnings and valuation, CODX or RADX?

Is CODX or RADX more profitable?

Summary

How does Co-Diagnostics compare to NextCure?

Is NXTC or CODX more profitable?

Which has more volatility and risk, NXTC or CODX?

Do insiders and institutionals hold more shares of NXTC or CODX?

Which has higher valuation & earnings, NXTC or CODX?

Does the media refer more to NXTC or CODX?

Do analysts rate NXTC or CODX?

Summary

How does Co-Diagnostics compare to Barinthus Biotherapeutics?

Do institutionals & insiders hold more shares of BRNS or CODX?

Does the media refer more to BRNS or CODX?

Is BRNS or CODX more profitable?

Do analysts prefer BRNS or CODX?

Which has more risk and volatility, BRNS or CODX?

Which has preferable earnings and valuation, BRNS or CODX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools